A Study of Ruxolitinib and Duvelisib in People With Lymphoma

Brief Summary

This study will test the safety of ruxolitinib, given at one dose that does not change, and duvelisib, given at different doses, to find out what effects, if any, the study treatment has on people with relapsed or refractory NK-cell or T-cell lymphoma.

Website: https://clinicaltrials.gov/study/NCT05010005

Sponsor: Memorial Sloan Kettering Cancer Center

Eligibility Criteria

Permitted histologies include:

i) Stage ≥Ib CTCL, which has relapsed or progressed after at least two systemic therapies.

For the following histologies, patients are required to have received at least 1 prior therapy:

xii) Primary cutaneous anaplastic large cell lymphoma

xiii) Primary cutaneous gamma/delta T-cell lymphoma

xiv) Primary cutaneous CD8-positive aggressive epidermotropic cytotoxic T-cell lymphoma

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. 

Please refer to this study by its ClinicalTrials.gov identifier: NCT05010005


Participating Locations:

Dana-Farber Cancer Institute
Boston, MA, United States
Eric Jacobsen, MD
Memorial Sloan Kettering Cancer Center
New York, NY, United States
Alison Moskowitz, MD